指南与共识流行病学与生物统计医学教育与科研方法

大疱性表皮松解症临床试验核心结局域集:COSEB达成「测什么」共识的方案

Core outcome domain sets for clinical trials in epidermolysis bullosa - a COSEB protocol to achieve consensus on "what" to measure.
指南 / 共识 · Trials · 2025-10-09

COSEB方案拟为四种主要大疱性表皮松解症(EB)类型制定临床试验核心结局域集,即所有试验应测量的最小结局集合。通过工作组、范围综述、定性研究、利益相关者咨询、德尔菲共识投票和共识会议确定候选与最终结局域,旨在标准化结局测量、提高研究可比性与数据合并。方案已于2017年10月23日在COMET注册(编号1033),2022年1月24日更新。

要点

  • COSEB拟为EB单纯型、交界型、营养不良型和Kindler型四种主要EB类型制定核心结局域集。
  • 利益相关者包括患者及代表、临床医生、研究者、方法学家、产业代表、监管者、卫生技术评估者和支付方。
  • 方案通过范围综述、定性研究、德尔菲共识投票和共识会议系统透明地确定「测什么」。

核心结论

  • 最终核心结局域集将作为未来EB临床试验应测量的最小集合,并为后续结局测量工具的选择提供基础。
  • 作者认为,在EB这种研究队列天然偏小的罕见病中,该核心结局域集有助于纳入有意义的结局并合并数据,最终优化EB的治疗。

研究设计与样本

  • COSEB为制定核心结局集(COS)的方案,聚焦于开发核心结局域集,即明确EB临床试验中应测量什么。
  • 目标是为四种主要EB类型制定核心结局域集:EB单纯型、交界型EB、营养不良型EB和Kindler型EB。
  • 利益相关者包括患者和患者代表、临床医生、研究者、方法学家、产业代表、监管者、卫生技术评估者和支付方。
  • 初阶段成立工作组,基于范围综述和定性研究确定四种主要EB类型的候选结局域长列表。
  • 经利益相关者顾问小组咨询后,候选结局域短列表进入德尔菲共识程序投票,并在共识会议上确认最终核心结局域集及任何总体核心结局域集。该方案已于2017年10月23日在COMET注册(编号1033),2022年1月24日更新。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epidermolysis bullosa (EB) comprises a heterogeneous group of rare, genetic blistering diseases. The wide variety in EB trial outcomes limits the comparability of outcomes and, consequently, the implementation of the best available treatment options. A core outcome set (COS) is a minimum set of outcomes that should be measured in all clinical trials, comprising what should be measured (i.e., outcome domains) and how it should be measured (i.e., outcome measurement instruments). This enables standardization of outcome measurement aiming at improving the comparability and quality of research. METHODS: The Core Outcome Set for Epidermolysis Bullosa (COSEB) initiative aims to develop COSs for use in clinical trials for the four major EB types: EB simplex, junctional EB, dystrophic EB, and Kindler EB. This protocol focuses on the development of core outcome domain sets - outlining what should be measured in EB clinical trials. Involved stakeholders are patients and patient representatives, clinicians, researchers, methodologists, industry representatives, regulators, health technology assessors, and payers. In the initial part, working groups are formed to define long lists of candidate outcome domains for the four major EB types. Potentially relevant outcome domains will be identified based on scoping literature reviews and qualitative studies. Following consultations with a stakeholder advisory panel, a short list of candidate outcome domains will be subject to voting in Delphi consensus procedures. Finally, the definitive core outcome domain sets for the four major EB types and, if indicated, any overarching core outcome domain sets, will be confirmed in consensus meetings. The project Has been prospectively registered in the COMET registry for COSs on 23 October 2017 (registration number 1033). DISCUSSION: This protocol provides guidance to ensure a systematic, transparent, and comprehensible approach of COSEB. The final core outcome domain sets are supposed to serve as the minimum sets of what to measure in future EB trials. This will provide the basis for the subsequent outcome measurement instrument selection. Particularly in this rare disease with inherently small-sized study cohorts, this will facilitate the incorporation of meaningful outcomes and pooling of data, ultimately enhancing optimal treatment for EB. TRIAL REGISTRATION: This study Has been prospectively registered in the COMET database on 23 October 2017 and updated on 24 January 2022 (registration number 1033 https://www.comet-initiative.org/studies/details/1033 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Korte EWH, van den Akker PC, Kiritsi D, et al. Core outcome domain sets for clinical trials in epidermolysis bullosa - a COSEB protocol to achieve consensus on "what" to measure. Trials. 2025. PMID: 41068902. doi:10.1186/s13063-025-09052-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。